Board Released New Report on Medicine Market Trends
The Patented Medicine Prices Review Board issued its 10th edition of the Meds Entry Watch report.
Updated on Oct. 14, 2026 in Economic Indicators
Live Poll
Should Canada prioritize faster access to the newest international pharmaceutical treatments?
The Patented Medicine Prices Review Board published its 10th edition of the Meds Entry Watch report, detailing market dynamics for pharmaceutical products. The study covers medicine uptake, pricing, and availability across international and domestic markets from 2021 through 2024.
Why it matters
This publication provides essential information for decision makers, researchers, and patients regarding the evolving market dynamics for emerging therapies in Canada. It tracks how new medical innovations are integrated into the domestic healthcare landscape.
Between 2021 and 2025, Health Canada granted market authorization to an average of 41 medicines annually. Of these approvals, an average of 14 medicines each year were specific treatments for rare diseases.
The players
Patented Medicine Prices Review Board
This independent quasi-judicial body is responsible for ensuring that the prices of patented medicines sold in Canada are not excessive.
Health Canada
This federal department is responsible for helping Canadians maintain and improve their health, including the regulation of pharmaceutical drugs.
The details
The report highlights that tirzepatide accounted for 47% of Q4 2024 sales for new medicines, while the Abrysvo RSV vaccine made up 12% of new-to-Canada sales. The analysis relied on data provided by the US Food and Drug Administration, the European Medicines Agency, and Health Canada.
Timeline
The Meds Entry Watch report was published on October 14, 2026.
The report covers data from 2021 through 2025.
Sales and market availability analysis used a data cutoff of Q4 2024.
Macro View
This analysis tracks long-term pharmaceutical adoption patterns that mirror the industry's shift toward specialized, rare-disease therapies. It follows a pattern set by the historical trend of rare disease drug authorization established by the Meds Entry Watch series.
This report highlights the increased availability of specialized treatments, which may influence future healthcare access and therapy options for Canadian patients. Understanding these market trends can help residents better anticipate the arrival and prevalence of emerging medical treatments.
The takeaway
The sustained high rate of new medicine approvals in Canada underscores the country's central role in the global pharmaceutical market. Patients should remain informed about these emerging therapies as they transition into standard clinical use.
Further reading
For more information on national financial trends, visit the Economic Indicators section.
Live Poll
Should Canada prioritize faster access to the newest international pharmaceutical treatments?
